- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03751072
Efficacy and Toxicity of Blinatumomab in the French ATU for Adult BCP-ALL R/R, or With MRD+ (FRENCH-CYTO) (FRENCH-CYTO)
Efficacy and Toxicity of Blinatumomab in the French Compassionate Use Program (ATU) for Adult Patients With B-cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) Refractory, in Relapse, or With Positive Minimal Residual Disease.
The outcome of young adults (18-60 years) with ALL has been dramatically improved by the use of pediatric-inspired trials. About 60% of these young adult patients will be cured at 5 years. In this context, early evaluation of minimal residual disease (MRD) at complete remission has been shown to be one of the most powerful prognostic factor, but also predictive of the benefit of allogeneic stem cell transplantation (ASCT). Despite this global improvement, about 30% of patients experience a relapse and will be exposed to be refractory to salvage therapy or to early disease escape. In adult ALL, the most important prognostic factors at relapse are : the time from first CR to relapse, the achievement of a second complete remission (CR), and the feasibility of ASCT.
Blinatumomab is a bispecific T-cell engager that recruits T-cell on CD19 positive blast cells and induces anti-leukemic cytotoxicity. In a phase 3 trial in relapse/refractory Philadelphia-negative (Ph-) ALL, 43% of patients achieved a CR or CR with partial hematological recovery (CRh), with the majority of responses occurring within the first cycle. In patients with positive MRD (MRD+) BCP-ALL, blinatumomab resulted in complete MRD response in 78% of patients after one cycle.
Between 2012 and 2016, blinatumomab was available in France for R/R and MRD+ ALL adult patients through the French Compassionate Use Program. About 92 adult ALL were treated at different stages of the disease in 27 centers.
Study Overview
Status
Detailed Description
To evaluate the efficacy of blinatumomab given in the French Compassionate Use Program, in term of overall survival in both R/R (first cohort) and MRD positive (second cohort) patients.
To evaluate the efficacy of blinatumomab given in the French Compassionate Use Program, in term of CR/CRH in R/R patients, To evaluate the efficacy in term of molecular response in both R/R and MRD+ cohorts, To evaluate the efficacy of blinatumomab given in the French Compassionate Use Program, in both Ph+/Ph- ALL patients To evaluate the feasibility and the safety of blinatumomab administration in a multi-center setting.To evaluate the feasibility of allogeneic stem cell transplant after blinatumomab administration in both populations.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
-
Paris, France, 75010
- Recruiting
- CABANNES-HAMY Aurélie
-
Contact:
- Aurélie CABANNES-HAMY, MD
- Email: aurelie.cabannes@aphp.fr
-
Contact:
- Nicolas BOISSEL, MD
- Email: nicolas.boissel@aphp.fr
-
Principal Investigator:
- Aurélie CABANNES-HAMY
-
Principal Investigator:
- Nicolas Boissel
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
Patient with Philadelphia-negative or positive (Ph+) ALL in relapse, refractory to salvage therapy, or with MRD positive ALL that received blinatumomab in the French ATU program.,
- Patient treated in the GRAALL network,
- Patient who does'nt object to participate in the study
Exclusion Criteria :
- none
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
Relapse/Refractory
|
MRD positive
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Survival in R/R and MRD+ cohorts
Time Frame: 6 months
|
Months
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Response rates
Time Frame: 6 months
|
Percent
|
6 months
|
Adverse events
Time Frame: 6 months
|
Percent
|
6 months
|
Disease free survival
Time Frame: 6 months
|
Months
|
6 months
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Nicolas BOISSEL, MD, 142499643
Publications and helpful links
General Publications
- Dombret H, Cluzeau T, Huguet F, Boissel N. Pediatric-like therapy for adults with ALL. Curr Hematol Malig Rep. 2014 Jun;9(2):158-64. doi: 10.1007/s11899-014-0210-9.
- Dhedin N, Huynh A, Maury S, Tabrizi R, Beldjord K, Asnafi V, Thomas X, Chevallier P, Nguyen S, Coiteux V, Bourhis JH, Hichri Y, Escoffre-Barbe M, Reman O, Graux C, Chalandon Y, Blaise D, Schanz U, Lheritier V, Cahn JY, Dombret H, Ifrah N; GRAALL group. Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia. Blood. 2015 Apr 16;125(16):2486-96; quiz 2586. doi: 10.1182/blood-2014-09-599894. Epub 2015 Jan 13.
- Gokbuget N, Stanze D, Beck J, Diedrich H, Horst HA, Huttmann A, Kobbe G, Kreuzer KA, Leimer L, Reichle A, Schaich M, Schwartz S, Serve H, Starck M, Stelljes M, Stuhlmann R, Viardot A, Wendelin K, Freund M, Hoelzer D; German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia. Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. Blood. 2012 Sep 6;120(10):2032-41. doi: 10.1182/blood-2011-12-399287. Epub 2012 Apr 4.
- Topp MS, Gokbuget N, Stein AS, Zugmaier G, O'Brien S, Bargou RC, Dombret H, Fielding AK, Heffner L, Larson RA, Neumann S, Foa R, Litzow M, Ribera JM, Rambaldi A, Schiller G, Bruggemann M, Horst HA, Holland C, Jia C, Maniar T, Huber B, Nagorsen D, Forman SJ, Kantarjian HM. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2015 Jan;16(1):57-66. doi: 10.1016/S1470-2045(14)71170-2. Epub 2014 Dec 16. Erratum In: Lancet Oncol. 2015 Apr;16(4):e158.
- Gokbuget N, Dombret H, Bonifacio M, Reichle A, Graux C, Faul C, Diedrich H, Topp MS, Bruggemann M, Horst HA, Havelange V, Stieglmaier J, Wessels H, Haddad V, Benjamin JE, Zugmaier G, Nagorsen D, Bargou RC. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood. 2018 Apr 5;131(14):1522-1531. doi: 10.1182/blood-2017-08-798322. Epub 2018 Jan 22. Erratum In: Blood. 2019 Jun 13;133(24):2625.
- Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95. doi: 10.1182/blood-2014-05-552729. Epub 2014 May 29. Erratum In: Blood. 2015 Aug 20;126(8):1048. Dosage error in article text. Blood. 2016 Sep 15;128(11):1533.
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- FRENCH-CYTO
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Lymphoblastic Leukemia, in Relapse
-
Institut Paoli-CalmettesINATHERYSRecruitingAcute Lymphoblastic Leukemia, in Relapse | Acute Myeloid Leukemia, in Relapse | Mixed Phenotype Acute Leukemia | Acute Lymphoblastic Leukemia Recurrent | Acute Myeloid Leukaemia RecurrentFrance
-
Federal Research Institute of Pediatric Hematology...RecruitingAcute Myeloid Leukemia | Myelodysplastic Syndromes | Acute Lymphoblastic Leukemia, in Relapse | Non-hodgkin Lymphoma | High Risk Acute Myeloid Leukemia | High Risk Acute Lymphoblastic Leukemia | Acute Biphenotypic Leukemia in RelapseRussian Federation
-
Beijing Boren HospitalRecruitingAcute Lymphoblastic Leukemia, Pediatric | Acute Lymphoblastic Leukemia, in Relapse | Refractory Acute Lymphoblastic LeukemiaChina
-
Andrew E. Place, MDUniversity of Colorado, Denver; AbbVie; Boston Children's Hospital; Gateway for... and other collaboratorsRecruitingAcute Lymphoblastic Leukemia, in Relapse | Therapy-Related Myelodysplastic Syndrome | Acute Leukemia of Ambiguous Lineage | Acute Leukemia of Ambiguous Lineage in Relapse | Myelodysplastic Syndromes, Previously Treated | Acute Lymphoblastic Leukemia With Failed Remission | Myelodysplastic Syndromes... and other conditionsUnited States
-
University of BirminghamAstraZeneca; Cancer Research UKTerminatedAcute Lymphoblastic Leukemia | Acute Lymphoblastic Leukemia, Pediatric | Acute Lymphoblastic Leukemia, in Relapse | Acute Lymphoblastic Leukemia, Adult | Acute Lymphoblastic Leukemia RecurrentUnited Kingdom, Denmark, Netherlands
-
St. Jude Children's Research HospitalActive, not recruitingAcute Lymphoblastic Leukemia, in Relapse | Acute Lymphoblastic Leukemia, RefractoryUnited States
-
Beijing Boren HospitalRecruitingAcute Lymphoblastic Leukemia | Acute Lymphoblastic Leukemia, in Relapse | Refractory Acute Lymphoblastic LeukemiaChina
-
Assistance Publique - Hôpitaux de ParisRecruitingAcute Lymphoblastic Leukemia, in Relapse | B Acute Lymphoblastic LeukemiaFrance
-
Chongqing Precision Biotech Co., LtdRecruitingAcute Lymphoblastic Leukemia, in Relapse | Refractory Acute Lymphoblastic LeukemiaChina
-
University College, LondonNot yet recruitingAcute Lymphoblastic Leukemia, Pediatric | Acute Lymphoblastic Leukemia, in Relapse | Acute Lymphoblastic Leukemia, Adult | Acute Lymphoblastic Leukemia With Failed Remission | Acute Lymphoblastic Leukemia Not Having Achieved Remission